1. Home
  2. SA vs RCUS Comparison

SA vs RCUS Comparison

Compare SA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seabridge Gold Inc. (Canada)

SA

Seabridge Gold Inc. (Canada)

HOLD

Current Price

$28.56

Market Cap

2.7B

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$21.33

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SA
RCUS
Founded
1979
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SA
RCUS
Price
$28.56
$21.33
Analyst Decision
Strong Buy
Buy
Analyst Count
1
8
Target Price
$65.00
$29.38
AVG Volume (30 Days)
1.0M
2.1M
Earning Date
11-12-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$240,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.40
$6.50
52 Week High
$31.35
$26.40

Technical Indicators

Market Signals
Indicator
SA
RCUS
Relative Strength Index (RSI) 56.70 42.60
Support Level $27.78 $20.35
Resistance Level $31.19 $26.10
Average True Range (ATR) 1.40 1.48
MACD 0.04 -0.59
Stochastic Oscillator 57.60 18.43

Price Performance

Historical Comparison
SA
RCUS

About SA Seabridge Gold Inc. (Canada)

Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: